Compare Nokia Corp (NOK) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs TG Therapeutics Inc — how do they compare? Nokia Corp trades at $10.81 (market cap $59.77B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: Nokia Corp is far larger — about 7× TG Therapeutics Inc's market cap, and Nokia Corp pays a 1.53% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NOK | TGTX | |
|---|---|---|
Market Cap | $59.77B | $8.53B |
Sector | Technology | Health |
52-Week High | $16.83 | $59.06 |
52-Week Low | $4.51 | $26.94 |
Enterprise Value | $57.71B | $8.74B |
Dividend Yield | 1.53% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $10.66, up 6.18% today, with a bullish technical signal and strong analyst support. Recent earnings show mixed quarterly beats, while revenue trends stabilize around $20B annually. The company maintains a solid balance sheet with $8.91B cash and reduced debt-to-asset ratio of 9.09 in 2025. Positive news includes AI-driven network expansion and Euro Stoxx 50 reinstatement, though cash flow volatility and competitive pressures persist.
Outlook: Growth is supported by AI infrastructure demand and portfolio diversification, but risks include execution challenges and margin pressures. With 61.5% analyst buy ratings and technical momentum, the stock offers upside potential, though investors should weigh high P/E of 76.42 against earnings consistency and free cash flow trends.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
